2019
DOI: 10.1016/j.ajoc.2019.100508
|View full text |Cite
|
Sign up to set email alerts
|

Vitrectomy for a secondary epiretinal membrane following treatment of adult-onset Coats’ disease

Abstract: Purpose To report a case of adult-onset Coats’ disease that had worsening of macular edema and progressive macular traction following cryotherapy and repeated intravitreal bevacizumab injections due to formation of a secondary epiretinal membrane which only improved following pars plana vitrectomy and membrane peeling. Observations A 35-year-old male presented with diminution of vision in his left eye and was found to have localized telangiectatic retinal vessels and an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 13 publications
0
6
0
Order By: Relevance
“…Diabetic macular edema (DME) is the most common cause of loss of vision in diabetic patients, affecting around 21 million people globally [1]. The treatment of macular edema associated with various retinal diseases, including DME (Figure 1), is currently dependent on the repeated intravitreal injection of different anti-vascular endothelial growth factor (anti-VEGF) agents [2][3][4][5][6]. Other treatment modalities for DME include steroid injections and macular laser photocoagulation [2].…”
Section: Introductionmentioning
confidence: 99%
“…Diabetic macular edema (DME) is the most common cause of loss of vision in diabetic patients, affecting around 21 million people globally [1]. The treatment of macular edema associated with various retinal diseases, including DME (Figure 1), is currently dependent on the repeated intravitreal injection of different anti-vascular endothelial growth factor (anti-VEGF) agents [2][3][4][5][6]. Other treatment modalities for DME include steroid injections and macular laser photocoagulation [2].…”
Section: Introductionmentioning
confidence: 99%
“…is occurs due to release of various inflammatory cytokines and growth factors, most importantly vascular endothelial growth factor (VEGF), following chronic hyperglycemia [6]. Several treatment modalities are available for DME, including the intravitreal injection of anti-VEGF drugs such as off-label intravitreal bevacizumab injections, which are also used in the treatment of macular edema associated with various other retinal conditions [7][8][9][10][11]. Because the therapeutic effect of these drugs is only temporary, however, long-term treatment is often required which raises concerns for worsening of macular ischemia and visual function due to chronic suppression of VEGF that could result in increased capillary dropout and inhibition of reperfusion of occluded capillaries [12,13].…”
Section: Introductionmentioning
confidence: 99%
“…In fact, it is the commonest cause of vision loss in diabetics and affects an estimated 21 million people worldwide [ 5 ]. Treatment of macular edema due to various retinal conditions, including DME, currently depends on the repeated intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents [ 6 - 9 ]. This may be due to the fact that VEGF is central to the pathogenesis of many of these retinal conditions including DR and DME [ 10 ].…”
Section: Introductionmentioning
confidence: 99%